Tempest Therapeutics, Inc. Stock price

Equities

TPST

US87978U1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.91 USD +5.39% Intraday chart for Tempest Therapeutics, Inc. +11.40% -11.14%
Sales 2024 * - Sales 2025 * - Capitalization 86.77M
Net income 2024 * -33M Net income 2025 * -43M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-2.77 x
P/E ratio 2025 *
-2.45 x
Employees 17
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.84%
More Fundamentals * Assessed data
Dynamic Chart
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13 MT
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types CI
North American Morning Briefing : Caution -2- DJ
Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Top Premarket Decliners MT
Health Care Down on Mixed Blessing of Obesity-Drug Promise -- Health Care Roundup DJ
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating MT
Tempest Therapeutics' TPST-1120 Combination Therapy Delivers Improved Results in Updated Liver Cancer Study; Shares Jump MT
Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study CI
Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development CI
Tempest Therapeutics, Inc. Announces Executive Changes CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers CI
More news
1 day+5.39%
1 week+11.40%
Current month+5.39%
1 month+4.27%
3 months-14.25%
6 months+1,067.16%
Current year-11.14%
More quotes
1 week
3.55
Extreme 3.55
3.99
1 month
3.03
Extreme 3.03
4.08
Current year
3.03
Extreme 3.03
4.81
1 year
0.17
Extreme 0.17
9.77
3 years
0.17
Extreme 0.17
41.00
5 years
0.17
Extreme 0.17
41.00
10 years
0.17
Extreme 0.17
41.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 19-08-31
Director of Finance/CFO 44 21-07-11
Chief Tech/Sci/R&D Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 56 21-06-30
Director/Board Member 69 19-11-30
Chairman 59 20-12-31
More insiders
Date Price Change Volume
24-03-28 3.91 +5.39% 677,974
24-03-27 3.71 0.00% 570,671
24-03-26 3.71 +1.92% 350,663
24-03-25 3.64 0.00% 442,468
24-03-22 3.64 +3.70% 556,065

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.91 USD
Average target price
18.6 USD
Spread / Average Target
+375.70%
Consensus
  1. Stock
  2. Equities
  3. Stock Tempest Therapeutics, Inc. - Nasdaq